Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
XiaoJiYin + erlotinib
- Development stage
- Unknown
- Lead developer
- Guangdong Provincial Hospital of Traditional Chinese Medicine
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
XiaoJiYin + erlotinib is a combination therapy comprising the Traditional Chinese Medicine (TCM) herbal formula XiaoJiYin and the small-molecule EGFR tyrosine kinase inhibitor erlotinib. Developed and studied by the Guangdong Provincial Hospital of Traditional Chinese Medicine, this combination is primarily targeted at patients with advanced non-small cell lung cancer (NSCLC), particularly those harboring EGFR mutations. XiaoJiYin is a complex herbal decoction intended to work synergistically with erlotinib to improve clinical outcomes, potentially by inhibiting tumor growth through multiple pathways, modulating the immune response, and delaying the onset of resistance to targeted therapy. Erlotinib acts by competitively inhibiting the adenosine triphosphate (ATP) binding site of the EGFR tyrosine kinase, thereby blocking downstream signaling pathways such as PI3K/Akt and MAPK/ERK that drive cell proliferation and survival.
- Other names
- Xiao-Ji-YinXiaojiyinXiaojiyin decoction
02
Targets
Beyond the preview
Go deeper on XiaoJiYin + erlotinib.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on XiaoJiYin + erlotinib.